Cellistic

CellisticAs a subsidiary of Ncardia, Cellistic™ was launched in April 2022, specializing in the process development and production of cell therapies based on human-induced pluripotent stem cell (iPSC) technology. Its focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development make it the preferred partner for innovative cell therapy developers looking to commercialize novel advanced therapies. Leveraging over a decade of scientific knowledge and experience from Ncardia, Cellistic possesses unique capabilities in designing and optimizing proprietary manufacturing platforms for iPSC-based cells, delivering high-quality products at scale.